| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DLL4 |
| Uniprot No | Q9NR61 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-524aa |
| 氨基酸序列 | SGVFQLQLQEFINERGVLASGRPCEPGCRTFFRVCLKHFQAVVSPGPCTF GTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIIEAWHAPG DDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICS DNYYGDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGC HEQNGYCSKPAECLCRPGWQGRLCNECIPHNGCRHGTCSTPWQCTCDEGW GGLFCDQDLNYCTHHSPCKNGATCSNSGQRSYTCTCRPGYTGVDCELELS ECDSNPCRNGGSCKDQEDGYHCLCPPGYYGLHCEHSTLSCADSPCFNGGS CRERNQGANYACECPPNFTGSNCEKKVDRCTSNPCANGGQCLNRGPSRMC RCRPGFTGTYCELHVSDCARNPCAHGGTCHDLENGLMCTCPAGFSGRRCE VRTSIDACASSPCFNRATCYTDLSTDTFVCNCPYGFVGSRCEFPVGLP |
| 预测分子量 | 56 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与DLL4重组蛋白相关的文献概览：
---
1. **文献名称**：*Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis*
**作者**：Ridgway, J. et al.
**摘要**：本研究证明通过重组DLL4蛋白或抗体阻断DLL4-Notch信号通路，可诱导肿瘤血管异常增生(非功能性血管生成)，从而抑制肿瘤生长，为抗血管生成治疗提供新策略(Nature, 2006)。
---
2. **文献名称**：*Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis*
**作者**：Noguera-Troise, I. et al.
**摘要**：利用重组DLL4蛋白激活Notch1通路，发现其通过抑制内皮细胞尖端化(tip cell formation)调控血管分支模式，揭示了DLL4在血管形态发生中的关键作用(Nature, 2006)。
---
3. **文献名称**：*DLL4-mediated Notch signaling regulates hematopoietic stem cell emergence*
**作者**：Yan, M. et al.
**摘要**：通过重组DLL4蛋白体外模拟Notch信号，证实DLL4对胚胎期造血干细胞(HSC)的发育至关重要，为造血系统疾病的治疗提供分子机制参考(Blood, 2010)。
---
4. **文献名称**：*Inhibition of Dll4 signaling inhibits tumor growth by disrupting functional tumor vasculature*
**作者**：Scehnet, J.S. et al.
**摘要**：利用重组DLL4拮抗剂(如DLL4-Fc融合蛋白)阻断Notch通路，导致肿瘤血管过度增生但功能失调，最终抑制肿瘤进展，验证了靶向DLL4的临床潜力(Blood, 2007)。
---
**备注**：以上研究均涉及重组DLL4蛋白在Notch信号通路、血管生成及肿瘤治疗中的机制探索或应用。如需具体引用格式或全文链接，可进一步补充数据库检索信息。
DLL4 (Delta-like ligand 4) is a transmembrane protein belonging to the Notch signaling ligand family, which plays a critical role in regulating cell fate determination, differentiation, and tissue development. As a key ligand for Notch receptors (Notch1/Notch4), DLL4 is essential for angiogenesis, particularly in vascular sprouting and remodeling during embryogenesis and pathological conditions like cancer. Its extracellular domain contains characteristic DSL (Delta/Serrate/LAG-2) and EGF-like repeats, enabling Notch receptor binding and activation through cell-cell contact.
Recombinant DLL4 proteins are engineered to study its biological functions or develop therapeutic strategies. These proteins typically include the extracellular domain (ECD) produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. Soluble DLL4-ECD retains the ability to bind Notch receptors, making it a tool for in vitro assays, angiogenesis studies, and Notch pathway modulation. Researchers also utilize Fc-fusion DLL4 proteins to enhance stability and mimic membrane-bound ligand clustering effects.
In cancer biology, DLL4 overexpression in tumor vasculature drives abnormal angiogenesis, promoting tumor growth and metastasis. Recombinant DLL4 is used to investigate mechanisms of resistance to anti-VEGF therapies and to develop DLL4-targeted biologics (e.g., antibodies, decoy receptors). However, therapeutic targeting requires caution, as global Notch pathway inhibition may cause gastrointestinal toxicity. Current studies focus on optimizing DLL4-based agents to balance efficacy and safety, highlighting its dual role as both a pro-angiogenic factor and a negative feedback regulator in vascular homeostasis.
×
